Eli Lilly and Company is seeking regulatory approval for its obesity medicines while expanding coverage through PBMs.
4 reports, 4 independent
Updated Aug 4
Gone quiet
Reached 3 outlets in its first 24 hours
- Reports
- 4
- Developments
- 2
- Repetition
- 75%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Eli Lilly and Company is seeking regulatory approval for its obesity medicines while expanding coverage through PBMs.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Cantor Fitzgerald lowered its price target for Eli Lilly and Company following data related to its obesity medicines.Sub-event
Lilly is seeking FDA approval for obesity medicines and expanding coverage via PBMs.1 source
Keep exploring
The entities involved
-
Eli Lilly and Company
American pharmaceutical company
-
Caremark
Care franchise based in the United Kingdom
- FDA
Related events
- Eli Lilly's tirzepatide proved more effective than Novo Nordisk's semaglutide in the obesity drug market.
- Eli Lilly and Novo Nordisk are competing for market share in the weight loss drug sector.
- BMS, Eli Lilly, and Novo Nordisk are advancing GLP-1 portfolios, investing in manufacturing, and navigating regulatory approvals.
- Major pharmaceutical companies, including Viking Therapeutics, Eli Lilly, and Novo Nordisk, are advancing their weight loss drug pipelines.
- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.